DANIEL KULICK: Open Payments
NPI 1720206600 · BROWN CITY, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$235 in 11 payments from 8 companies in 2025. Trend: 2023 $467 · 2024 $320 · 2025 $235
Food & beverage: $235
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 2 | $64 |
| Lilly USA, LLC | 2 | $38 |
| Novo Nordisk Inc | 2 | $33 |
| Supernus Pharmaceuticals, Inc. | 1 | $25 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Exact Sciences Corporation | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| ABBVIE INC. | 1 | $18 |
Products named: FARXIGA, MOUNJARO, Qelbree, Auvelity, Ozempic, The Cologuard Plus Collection Kit, REXULTI, QULIPTA.
Industry payments across MI — which companies pay providers there.
